"Interleukin-15" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
| Descriptor ID |
D019409
|
| MeSH Number(s) |
D12.644.276.374.465.515 D12.776.467.374.465.515 D23.529.374.465.515
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-15".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-15".
This graph shows the total number of publications written about "Interleukin-15" by people in this website by year, and whether "Interleukin-15" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 5 | 8 |
| 2018 | 7 | 6 | 13 |
| 2019 | 2 | 2 | 4 |
| 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-15" by people in Profiles.
-
Systemic IL-15, IFN-?, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 08 10; 36(6):109504.
-
NK cells on the ViP stage of COVID-19. EBioMedicine. 2021 Jul; 69:103458.
-
AI-guided discovery of the invariant host response to viral pandemics. EBioMedicine. 2021 Jun; 68:103390.
-
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021 03; 22(3):322-335.
-
An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021 01 11; 6(1).
-
A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted. Cytokine Growth Factor Rev. 2021 04; 58:49-50.
-
IL-15 immunotherapy is a viable strategy for COVID-19. Cytokine Growth Factor Rev. 2020 08; 54:24-31.
-
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019 12; 4(12):960-970.
-
Diabetes alters immune response patterns to acute melioidosis in humans. Eur J Immunol. 2019 07; 49(7):1092-1106.
-
A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. J Exp Med. 2019 06 03; 216(6):1255-1267.